PuraBond® in Robot-Assisted Radical Prostatectomy (RARP): Exploring a Novel Haemostatic Strategy Using...

Area of Science:

• Urology
• Surgical Innovation
• Biomaterials

Background:

• Robot-assisted radical prostatectomy (RARP) requires effective haemostasis for optimal patient outcomes.
• Conventional methods like diathermy and sutures may not always provide sufficient bleeding control in the prostate bed.
• Novel haemostatic agents are needed to improve intraoperative and postoperative bleeding management during RARP.

Purpose of the Study:

• To evaluate the safety and efficacy of PuraBond®, a self-assembling peptide (SAP) haemostatic agent, as an adjunct during RARP.
• To assess the impact of PuraBond® on intraoperative bleeding, postoperative haemostasis, and early functional outcomes following RARP.

Main Methods:

• A retrospective case series of 10 patients undergoing RARP with intraoperative PuraBond® application.
• Data collected included patient demographics, surgical parameters, estimated blood loss, transfusion requirements, and complications within 90 days.
• Postoperative urinary function (IPSS) and erectile function (IIEF) were assessed at follow-up visits.

Main Results:

• PuraBond® achieved effective haemostasis in all 10 patients with no intraoperative complications.
• No patients experienced postoperative bleeding or required blood transfusions.
• Successful trial without catheter (TWOC) in all patients, with favourable early urinary continence and low complication rates.

Conclusions:

• PuraBond® appears to be a safe and effective adjunct for haemostasis during RARP.
• The SAP agent demonstrated consistent haemostatic efficacy and contributed to favourable early postoperative outcomes.
• Further prospective controlled studies are recommended to compare PuraBond® with existing haemostatic techniques.